PD49-06 EFFICACY OF RESTOREX PENILE TRACTION THERAPY IN IMPROVING PENILE LENGTH AND ERECTILE FUNCTION POST PROSTATECTOMY

Abstract

You have accessJournal of UrologyCME1 May 2022PD49-06 EFFICACY OF RESTOREX PENILE TRACTION THERAPY IN IMPROVING PENILE LENGTH AND ERECTILE FUNCTION POST PROSTATECTOMY Andrew Zganjar, Amir Toussi, Matthew Ziegelmann, David Yang, Madeleine Manka, Tobias Kohler, Sevann Helo, and Landon Trost Andrew ZganjarAndrew Zganjar More articles by this author , Amir ToussiAmir Toussi More articles by this author , Matthew ZiegelmannMatthew Ziegelmann More articles by this author , David YangDavid Yang More articles by this author , Madeleine MankaMadeleine Manka More articles by this author , Tobias KohlerTobias Kohler More articles by this author , Sevann HeloSevann Helo More articles by this author , and Landon TrostLandon Trost More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002620.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Penile length loss and erectile dysfunction are common post-prostatectomy (post-RP). Recent results from a randomized, controlled study (RCT) of RestoreX penile traction therapy (RxPTT) demonstrated preserved erectile function and penile length improvements in men post-RP. The current objective is to report outcomes of the open label phase (6-9 month time point). METHODS: A randomized, controlled trial (NCT03500419) has been completed of 82 men. Men were randomized 1-month post-RP to no treatment (NoTx, n=27) or RxPTT (n=55) for 5 months. Participants then entered an open label phase for 3 months. Assessments included stretched penile length (corona), standardized (International Index of Erectile Function [IIEF]), and non-standardized questionnaires. Comparisons of changes from baseline were performed between cohorts using an as-treated analysis. RESULTS: Of the 82 men enrolled (mean age 58.6), 55 had 6-month, and 42 had 9-month data available to review. Baseline characteristics were similar between cohorts. In the as-treated analysis (NoTx x 8 months n=7, RxPTT x 8 months n=12, respectively), differences were as noted: IIEF-EFD (−8 vs −0.5, p=0.19), IIEF-OFD (−3 vs −2, p=0.86), IIEF-SD (−1 vs 0.5, p=0.09), IIEF-ISD (−3 vs −0.5, p=0.31), IIEF-OSD (−2 vs 0, p=0.29), penile length (−0.1 vs +1.8 cm, p <0.01), PDE5 use (86% vs 75%, p=0.57), intracavernosal injection use (86% vs 17%, p <0.01). Comparisons of men who were NoTx x 8 months (n=7) to those crossing over to RxPTT during the open label phase (n=8) demonstrated: IIEF-EFD (−8 vs −6, p=0.49), IIEF-OFD (−3 vs −1, p=0.90), IIEF-SD (−1 vs 0, p=0.55), IIEF-ISD (−3 vs −1, p=0.45), IIEF-OSD (−2 vs −1, p=0.51), penile length (−0.1 vs +0.69 cm, p=0.39). Men who crossed over from RxPTT to NoTx (n=10) had relatively preserved improvements compared to those who continued with RxPTT during the open label phase (n=12): IIEF-EFD (0 vs −0.5, p=0.95), IIEF-OFD (−3.5 vs −2, p=0.97), IIEF-SD (0 vs 0.5, p=0.18), IIEF-ISD (0 vs −0.5, p=0.87), IIEF-OSD (0 vs 0, p=0.66), penile length (+1.8 vs +1.8, p=0.99). CONCLUSIONS: Although sample size and statistical power are limited, results from the open label phase confirm earlier findings of preserved sexual function and penile length in men treated with RxPTT compared to controls. Men who crossed over from controls to Tx experience benefits, although not as significant as those who were treated beginning at 1 month post-prostatectomy. Men who stopped Tx after 6 months demonstrated stable improvements from baseline, suggesting a preserved effect of RxPTT even after discontinuing use. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e832 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Andrew Zganjar More articles by this author Amir Toussi More articles by this author Matthew Ziegelmann More articles by this author David Yang More articles by this author Madeleine Manka More articles by this author Tobias Kohler More articles by this author Sevann Helo More articles by this author Landon Trost More articles by this author Expand All Advertisement PDF DownloadLoading ...